CG0070 for Bladder Cancer (CORE-001 Trial)

"CG0070's efficacy has not been proven, but it did receive a score of 2 for safety."

"According to the latest information available on clinicaltrials.gov, this particular trial is not looking for new candidates at the moment. The study was first made public on December 8th 2020 but has not been updated since August 22nd of 2022. Although this research is closed to recruitment, there are 1,331 other trials that are still open and enrolling patients."

"City of Hope first began studying CG0070 in 2010 and there have been 248 completed trials to date. There are 1002 open studies at the moment, a large concentration of which are taking place in Lancaster, Pennsylvania."

"This clinical trial is currently enrolling patients at 13 sites across the United States. The sites are located in Lancaster, Baltimore, Orange, and other cities. If you enroll in the trial, it is important to select a location that is nearest to you to minimize travel requirements."

"CG0070 is most frequently used to treat patients with malignant neoplasms. However, this medication can also be effective in managing unresectable melanoma, microsatellite instability high, and chemotherapy-resistant disease progression."

"Unfortunately, this particular clinical trial is not currently enrolling patients. Although, it's worth noting that the last update was on 8/22/2022 and the study originally posted on 12/8/2020. There are other329 trials actively recruiting participants with urinary bladder cancer and 1002 studies for CG0070 actively recruiting participants if you're interested in finding another study to join."